{"schema_version":"secwatch.filing_event.v1","accession":"0001390478-24-000011","form_type":"8-K","ticker":"SLS","cik":"0001390478","company_name":"SELLAS Life Sciences Group, Inc.","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.198967+00:00","generated_at":"2026-06-02T00:32:54.979049+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"SELLAS Q1 net loss $9.6M; Phase 2 SLS009 100% response in ASXL1 AML; IDMC backs REGAL trial","bullets":["Net loss of $9.6M ($0.21/share) vs $11.1M ($0.47/share) in Q1 2023.","Cash and equivalents $18.4M at March 31, 2024; R&D expense $5.1M, G&A $4.5M.","IDMC recommends continue Phase 3 REGAL (GPS in AML) without modification; next review June 2024 of all 127 patients.","SLS009 Phase 2: 62% anti-leukemic activity all doses, 67% at 30mg BIW; 100% ORR in ASXL1 mutation patients at 30mg BIW; cohort expanding.","Phase 3 REGAL enrollment completed; provisional patent filed for SLS009 in ASXL1-mutated AML."],"urls":{"canonical":"https://secwatch.observer/filing/0001390478-24-000011","json":"https://secwatch.observer/filing/0001390478-24-000011.json","markdown":"https://secwatch.observer/filing/0001390478-24-000011.md","text":"https://secwatch.observer/filing/0001390478-24-000011.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1390478/000139047824000011/0001390478-24-000011-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1390478/000139047824000011/sls-20240514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T00:32:54.979049+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3d22fac0c23e3ff2342a6afce02b7876578c5f24","claim":"SELLAS Life Sciences Group, Inc. reported the first quarter ended March 31, 2024 results: net income $9.6 million, EPS $0.21.","evidence_excerpt":"SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1390478/000139047824000011/0001390478-24-000011-index.htm","confidence":0.92,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Net income","value":"$9.6 million"},{"label":"EPS","value":"$0.21"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}